



RhAPP

RHEUMATOLOGY ADVANCED
PRACTICE PROVIDERS

Inaugural National Conference

December 3 – 5, 2020

VIRTUAL CONFERENCE



RhAPP

RHEUMATOLOGY ADVANCED
PRACTICE PROVIDERS



Hematology

Beth Faiman, PhD, MSN, APRN, BC,
AOCN[®], FAAN

Nurse Practitioner, Department of Hematology and Oncology
Cleveland Clinic Taussig Cancer Institute
Cleveland, Ohio

Disclosure

All faculty and staff involved in the planning or presentation of continuing education activities provided by the Annenberg Center for Health Sciences at Eisenhower (ACHS) are required to disclose to the audience any real or apparent commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity. All staff at the Annenberg Center for Health Sciences at Eisenhower and Rheumatology Advanced Practice Providers (RhAPP) have no relationships to disclose.

Faculty Disclosures

Beth Faiman, PhD, MSN, APRN, BC, AOCN[®], FAAN

- There are currently no relationships to disclose.

Objectives

- In this workshop we will review:
 - Normal and abnormal hematopoiesis
 - Common (and less common) blood disorders
 - Malignant blood disorders

What Is Hematology?


- The study of the normal and pathologic aspects of blood and blood elements
- The cellular elements that arise from the hematopoietic stem cell normally circulate in blood
 - Red blood cells (RBCs),
 - Platelets
 - White blood cells (WBCs)
 - Neutrophils, monocytes, lymphocytes, eosinophils, basophils

Numerous Benign Heme Disorders

- Iron deficiency anemia
- Megaloblastic anemia (vitamin B12 and folic acid deficiency)
- Congenital hemolytic anemia
- Thalassemias
- Sickle cell disease
- Hemolytic anemia
- Paroxysmal nocturnal hemoglobinuria (PNH)
- Factor VIII deficiency (hemophilia A)
- Factor IX deficiency (hemophilia B)
- Factor XI deficiency (hemophilia C)
- Factor V, X, and II disorders
- Factor XIII deficiency
- Von Willebrand Disease
- Waldenstrom Macroglobulinemia
- Transfusion therapy
- Disseminated Intravascular Coagulation (DIC)
- Thrombocytopenia
- Immune Thrombocytopenia Purpura (ITP)
- Thrombotic Thrombocytopenia Purpura (TTP)
- Hemolytic Uremic Syndrome (HUS)
- Primary Thrombocytosis
- Thrombosis
- Cancer Associated Thrombosis
- Neutrophilia
- Neutropenia
- Chediak-Higashi syndrome (CHS)
- Leukocyte adhesion deficiency
- Eosinopenia
- Eosinophilia
- Monocytopenia
- Monocytosis
- Aplastic Anemia
- Monoclonal Gammopathy of Unknown Significance (MGUS)



Normal and Abnormal Stem Cell Development



Erythrocytes (RBCs)

- Non-nucleated cells that package **hemoglobin**, the protein that carries oxygen to and carbon dioxide from tissues.
- Erythropoiesis is regulated by the growth factor **erythropoietin** and takes 4 days.
- Reticulocyte counts reflect the percentage of early RBCs in the total number of RBCs in the circulation.
Normal count: less than 2%.
- RBC lifespan is 120 days.




Camaschella C. Iron deficiency: new insights into diagnosis and treatment. *Hematology Am Soc Hematol Educ Program*. 2015;2015:8-13. doi: 10.1182/asheducation-2015.1.8. PMID: 26637694;

Mithoowani S, Laureano M, Crowther MA, Hillis CM. Investigation and management of erythrocytosis. *CMAJ*. 2020 Aug 10;192(32):E913-E918. doi: 10.1503/cmaj.191587. PMID: 32778603.

<http://criticalcaredvm.com/wp-content/uploads/2015/03/6-red-blood-cells-sem-susumu-nishinaga.jpg>


Neutrophils

- Nucleus that is usually a 3- or 4-lobed structure and stains a bluish color.
- An early form of a neutrophil is a band that shows an unsegmented neutrophil.
- Role: phagocytize and digest bacteria, cellular debris, and dead tissue.
- Normally takes 12-13 days to be produced in bone marrow.
- Lifespan in the circulation: About 12 hours, but it can live in tissues for several days.
- Only half of the neutrophils that are circulating are reflected in the WBC count. In adults, they constitute 50-80% of the total WBC counted.



Monocytes

- Large, mononuclear cells with an indented nucleus (kidney shaped).
- Host defense against organisms while in the circulation (similar to that of neutrophils).
- Spend 1-3 days in the bone marrow and 8-72 hours in the peripheral blood.
- Once they traverse into tissues, they can differentiate into macrophages, and survive in tissues for long periods (up to 80 days).




Macrophages

- Macrophages are characterized by and named for their tissue origin (e.g., alveolar macrophages in lungs, Kupffer cells in liver, splenic macrophages, and oligodendrocytes or glial cells in the brain).
- Role of macrophages: *phagocytize pathogens, cellular debris, and dead tissue.*


Eosinophils

- Prominent reddish orange granules, usually have bilobed nuclei
- Increase the reaction to foreign proteins |(seen in parasitic infections, allergic conditions, cancer, and certain drugs)
- Normally, constitute 0%-2% of WBC count




Basophils

- Colorful cells with very dark bluish prominent granules
- Granules contain histamine, heparin, and hyaluronic acid
- Histamine release (basophil degranulation) is part of allergic reactions
- Normally, basophils constitute 1% of the WBC count. Higher counts are often higher in patients with myeloproliferative disorders



Platelets

- Nonnucleated cell fragments that contain messenger RNA
- Derived from the cytoplasm of the bone marrow megakaryocytes; growth regulated by thrombopoietin
- Lifespan: 8-10 day; first 1-2 days in the spleen.
- Platelets can be entrapped by an enlarged spleen, as seen in congestive or inflammatory disorders.
- Play an important role in hemostasis because they contain many hemostatic cofactors and inhibitors in their granules.



The Complete Blood Count: Cytopenias

- Leukopenia
- Neutropenia
 - Granulocyte percentage
 - Absolute granulocyte
- Thrombocytopenia

| Lab/Normal Reference Range | Value |
|-------------------------------------|----------|
| WBC: 4.0–11.0 k/uL | 1.92 |
| Plt: 150–400 k/uL | 209 |
| MPV: 9.0–12.7 fL | 9.4 |
| Neutrophil: 38.5%–75.0% | 48.0 (L) |
| Absolute neutrophil: 1.00–7.50 k/uL | 0.92 (L) |
| Lymphocyte: 15.9%–47.3% | 35.5 |
| Absolute lymphocyte: 1.00–4.00 k/uL | 1.69 |



RhAPP

RHEUMATOLOGY ADVANCED
PRACTICE PROVIDERS

Evaluation of Anemia

Mechanisms of Anemia

1. *Bleeding*: The loss of RBCs (GI tract, menstruation)
2. *Increased destruction*: a shortened RBC survival time not explained by bleeding (hemolysis)
3. *Decreased production* of RBCs from underlying causes
 - Nutritional deficiencies (iron, vitamin B12, folic acid, copper, zinc)
 - Kidney disease
 - Anemia of chronic disease
 - Primary bone marrow disorder (Myelodysplasia, leukemia, aplastic anemia)

The Complete Blood Count: Anemia (Cont.)

- Workup for anemia
 - LDH
 - Monoclonal Protein
 - Haptoglobin, coombs
 - Retic
 - Iron studies (Iron+Tibc, Ferritin)
 - TSH
 - EPO
 - B12, MMA
 - Folate
 - Zinc/Copper??
 - CRP/ESR
 - BUN/Cr
 - Hb electrophoresis
 - H. Pylori if sx and IDA
- Lab values vary slightly amongst institutions and laboratories

| Lab/Normal Reference Range | Value |
|----------------------------|------------|
| Ferritin: 18.0–300.0 ng/mL | 22 |
| TIBC: 210–415 ug/dL | 440 |
| Iron: 30–140 ug/dL | 99 |
| Folate: 2–18 ng/mL | > 18 |
| MMA: 79–376 nmol/L | 399 |
| Vitamin B12: 221–700 pg/mL | 200 |

Overview of Hematologic Cancers. December 4, 2020 | 19.

TIBC = total iron binding capacity; MMA = methylmalonic acid.

NCCN. 2020; Sankaran V. G., & Weiss M. J. (2015). Anemia: progress in molecular mechanisms and therapies.

Nature Medicine. 21(3), 221–230. <https://doi.org/10.1038/nm.3814>

Evaluation of Anemia: Normal Test Ranges


| Laboratory Test | Normal Value |
|-----------------------------------|--|
| Red blood cell count | Male: 4.7–6 million cells/mcl; female: 4.2–5.4 million cells/mcl |
| Hemoglobin | Male: 13.5–18 g/dl; female: 12–16 g/dl |
| Hematocrit | Male: 42%–52%; female: 37%–47% |
| Mean corpuscular volume | 78–100 fL |
| Mean corpuscular hemoglobin | 27–31 pg/cell |
| Red cell distribution width | 11.5%–14% |
| Reticulocyte count | 0.5%–1.85% of erythrocytes |
| Ferritin | Male: 20–300 ng/ml; female: 15–120 ng/ml |
| Serum iron | Male: 75–175 mcg/dl; female: 65–165 mcg/dl |
| Total iron-binding capacity | 250–450 mcg/dl |
| Serum erythropoietin level | Male: 17.2 mU/ml; female: 18.8 mU/ml |
| Coombs test (direct and indirect) | Negative |
| Serum B ₁₂ | 190–900 ng /ml |
| Serum folate | > 3.5 mcg/L |

Overview of Hematologic Cancers. December 4, 2020 | 20.

Table 111-1. Laboratory Assessment of Anemia: Normal Values (Adults) Faiman, 2013.

Clin Manual for APNs. ONS publishing.

First, Check the Size of the RBC (MCV)



Next, Look at Reticulocyte Count


- Young erythrocytes
- In an anemia, the reticulocyte% must be corrected for the severity of anemia to obtain reticulocyte production index
- **Elevated:** suggests RBC loss (bleeding) or destruction
- **Normal or decreased:** defective production of RBCs, acute blood loss, RBC destruction, vitamin or mineral deficiency, bone marrow depression (drugs, chronic infection, chronic inflammation, malignancy), and defective RBC production (kidney disease, myelodysplastic syndrome, pure red cell aplasia, lead poisoning, and alcoholism)

Macrocytic Anemia

MCV > 100

- **Elevated Retics**

- Autoimmune hemolytic anemia
- Cold agglutinins
- Non-immune hemolysis
- Acute blood losses



- **Low or semi-normal**

- B12 deficiency
- Folate deficiency
- MDS
- Aplastic anemia
- Hypothyroidism
- Drugs that cause macrocytosis, e.g. Etoh, HIV drugs, TMP/Sulfa

Serum Vitamin B12 Level

- Some situations may lead to levels that are falsely low (folate deficiency, pregnancy, oral contraceptives), elevated (liver disease, CML), or normal
- **Homocysteine level:** when elevated, can mean either vitamin B12 or folic acid deficiency
- **Methylmalonic acid:** elevated only in patients with vitamin B12 deficiency

Treatment Deficiency

Treatment B12 Deficiency: -1 mg IM daily for 3-7 days; 1 mg IM weekly for 4-8 weeks, then 1 mg IM monthly for life

- Can also be given orally (sublingual)

Treatment Folic Acid Deficiency: Oral is typically used 1-5 mg daily

- Given prophylactically in women contemplating pregnancy to prevent neural tube defects, pregnant or lactating women, and patients with chronic hemolysis and increased erythropoiesis
- Elevated homocysteine levels have been associated with an increased risk for cardiovascular disease, so these patients should be treated with folic acid (decreases homocysteine levels)

Microcytic Anemia

MCV < 80

- Iron deficiency the most common
 - MCHC also low as well as MCV
- Thalassemias
 - Alpha – needs DNA studies (Alpha Thal gene deletion)
 - Beta – Hgb HPLC/electrophoresis; Hgb A2↑
- Hemoglobinopathies
- Anemia of Chronic inflammation/disease
- Sideroblastic anemia

Iron Deficiency Anemia: Overview

- Ferritin is the major storage form of iron, sequestered in a nontoxic form and available for future use.
- The metabolism of iron is dominated by its role in hemoglobin synthesis.
- **Metabolism:** Iron is absorbed from the duodenum and proximal jejunum in the GI tract or modified from iron stores in the liver. It then enters the plasma, where it is bound to transferrin. The circulating iron is transported from the plasma to cells that have the capacity to make Hgb in the bone marrow.
- Colonoscopy/EGD if anemia suspected.

Iron Excretion


- No physiologic mechanism for iron excretion
- Iron is lost from the body only when cells are lost, especially epithelial cells in the GI tract, skin, and renal tubules
- Normally, 1-2 mg of iron is lost each day
- Menstruating women lose an additional 0.006 mg/kg/day of iron (on average) prorated over the entire menstrual cycle-more with menorrhagia!
- Pregnant women lose iron at a rate approximately 3.5 times that of normal men (goes to fetus)



Etiology of Iron Deficiency

A number of clinical situations can lead to iron deficiency:

- Increased iron requirements due to physiologic stresses (growth, pregnancy, lactation)
- Increased iron requirements due to pathologic causes (blood loss)
- Inadequate iron supply (consumption of foods low in iron, impaired absorption of iron, abnormal transferrin function)



Testing for Iron Deficiency

Leads to other answers for microcytosis

| | | | | | |
|--------------------|-----------------------------|---------------------|----------|-----------------------|--------------------------------------|
| Ferritin | N/↑ | N/↑ | Low | High | N |
| Serum Iron | N/↑ | Low | Low | High | N |
| TIBC | N | N/Low | High | Low | N |
| % Sat | N | Low/N | Low | High | N |
| Dx or next? | Thal Hgb electrophoresis | Inflam; chr disease | Iron def | Sidero-blastic | Hgb problem; Hgb electro-phoresis |

Oral Iron Repletion

- Ferrous salts absorbed better than ferric
 - Ferrous sulfate ~65mg elemental iron daily; 1 tablet of the standard 324mg preparation
 - Ferrous gluconate, ferrous fumarate, iron polysaccharide
 - Not enteric-coated
- Absorption in duodenum; best with acidic environment & fasting
- Treat for 3-6 months AFTER CBC has normalized
- Side effects: constipation, GI upset, nausea, sometimes diarrhea



Parenteral Iron Therapy

- Failure of oral therapy; severe losses; malabsorption esp Roux-en-Y bypass
- Iron dextran – 25mg test dose; can give up to 1 gram in normal saline over 4-5 hours
- Ferric sucrose (Venofer), ferric gluconate (Ferrlecit), ferumoxytol (Feraheme), ferric carboxymaltose (Injectafer)
 - No test dose; 100mg to max 750 mg/day
 - Large doses can cause acute iron toxicity
- Side Effects: fever, HA, myalgia/arthritis, anaphylactic shock



A Classic Iron Deficient Patient

- 42 YO w/ psoriatic arthritis
- Increased fatigue; diagnosed with iron def anemia 2016
- Placed on oral iron for 2 months then stopped due to side effects of constipation
- Due to fatigue, counts rechecked in May 2017:
- **Treatment:** IV iron
- Injectafer 750 mg weekly x 2 (1500 mg total)
- Reassess 8 weeks post last iron infusion


Laboratory Results

| Component | Latest Ref Rng & Units | 4/23/2016 | 8/9/2016 | 5/10/2017 |
|------------------------|------------------------|-----------|----------|-----------|
| WBC | 3.70 - 11.00 k/uL | 7.07 | 7.80 | 9.90 |
| RBC | 3.90 - 5.20 m/uL | 4.29 | 4.44 | 4.07 |
| Hemoglobin | 11.5 - 15.5 g/dL | 8.4 (L) | 11.5 | 7.7 (L) |
| Hematocrit | 36.0 - 46.0 % | 29.5 (L) | 37.1 | 27.5 (L) |
| MCV | 80.0 - 100.0 fL | 68.8 (L) | 83.6 | 67.6 (L) |
| MCH | 26.0 - 34.0 pG | 19.6 (L) | 25.9 (L) | 18.9 (L) |
| MCHC | 30.5 - 36.0 g/dL | 28.5 (L) | 31.0 | 28.0 (L) |
| RDW-CV | 11.5 - 15.0 % | 19.3 (H) | 17.3 (H) | 19.8 (H) |
| Platelet Count | 150 - 400 k/uL | 427 (H) | 362 | 496 (H) |
| MPV | 9.0 - 12.7 fL | 9.3 | 9.8 | 9.5 |
| Neut% | % | 62.7 | | 61.4 |
| Abs Neut (ANC) | 1.45 - 7.50 k/uL | 4.43 | | 6.08 |
| Lymph% | % | 21.2 | | 28.2 |
| Abs Lymph | 1.00 - 4.00 k/uL | 1.50 | | 2.79 |
| Mono% | % | 10.3 | | 6.3 |
| Abs Mono | 0.00 - 0.86 k/uL | 0.73 | | 0.62 |
| Eosin% | % | 5.2 | | 3.4 |
| Abs Eosin | 0.00 - 0.45 k/uL | 0.37 | | 0.34 |
| Baso% | % | 0.6 | | 0.7 |
| Abs Baso | 0.00 - 0.10 k/uL | 0.04 | | 0.07 |
| Nucleated Reds | 0 /100 WBC | | | 0.0 |
| NRBC | 0 /100 WBC | | | 0 |
| Absolute nRBC | k/uL | | | 0.00 |
| Diff Type | | Auto Diff | | Auto Diff |
| Iron | 41 - 186 ug/dL | | 20 (L) | 12 (L) |
| TIBC | 232 - 386 ug/dL | | 356 | 372 |
| Transferrin Saturation | 15 - 57 % | | 6 (L) | 3 (L) |
| Retic % | 0.4 - 2.0 % | | | 2.2 (H) |
| Abs Retic | 0.0180 - 0.1000 M/uL | | | 0.088 |
| Ferritin | 14.7 - 205.1 ng/mL | | 26.9 | 5.5 (L) |

CBC + DIFF
Reference Range & Units: %

Normocytic Anemia

- Can be the hardest to diagnose properly
- Retics usually normal or decreased
- Most frequently needs a bone marrow to diagnose
- Other concurrent medical conditions become very important; liver, kidney, endocrine, inflammatory, malignant disease



Normocytic Anemia

Endocrine disease

Hypothyroidism

Hyperthyroidism

Addison's disease

Panhypopituitarism

Testicular failure

Renal disease

High creatinine

Low, inappropriately low

Epo

Mineral imbalance

Copper deficiency

Zinc overload

If No liver, renal, or endocrine disease or esp if high epo level

Needs a marrow exam

Hypoplasia/aplastic anemia

Leukemia/malignant infiltration

Myelodysplastic syndromes

Thrombocytopenia

- Definition
 - Less than 150,000/ul
 - May have some slight local variance
- Pseudothrombocytopenia
 - 1:1000 to 1:10,000 specimens
 - EDTA clumping
 - Typically solved with citrate or heparinized tube
 - Found on peripheral smear exam

History Questions Thrombocytopenia

- What medications is the patient taking?
Which ones are new?
- Alcohol exposure?
- Recent transfusions?
- Are there HIV risk factors?
- Is there a family history of thrombocytopenia?

Physical Examination

- Petechiae
 - Dependent, traumatized areas
 - Mucous membrane, epistaxis, GI bleeding
- Purpura
- > 50,000 counts rarely associated with any increase in hemorrhage
- Adenopathy, splenomegaly, hepatomegaly

Acquired Production Problems

- Marrow infiltration
 - Replacement of normal hematopoietic elements with something else
 - Possible inhibitory effect of secondary process affecting mega function
- Treat the underlying process to improve platelet count
- Cancer, leukemia, lymphoma, multiple myeloma
- Myelofibrosis
- Osteoporosis
- Infectious processes
- Toxins, Viruses
- Drugs
- Folate/B12/iron deficiency
- Pure amegakaryocytic thrombocytopenia
- Myelodysplastic syndrome

Drugs Are a Common Cause

- Hospital:
 - Heparin, LMWH, sulfa, valproic acid, quinine/quinidine, gold salts, penicillins, vancomycin, linezolid, cephalosporins, cocaine
 - Anti-IIb/IIIa drugs – can cause acute severe drops
- Outpatient:
 - Quinidine, quinine, rifampin, digoxin
 - Acetaminophen, Bactrim, danazol, cimetidine, chlorothiazide, lithium diazepam, sulfisoxazole
 - Piperacillin, methicillin
 - Minoxidil, DES, nitroglycerin, tamoxifen
 - Zantac, Tegretol, Dilantin, Motrin, captopril, ampicillin, procainamide, HCTZ

What Is ITP?

- **I**diopathic (or **I**mmune) **T**hrombocytopenic **P**urpura
 - Acquired autoimmune disorder
 - Antibodies or activated T cells targeted against platelets leading to their destruction
- Two major criteria for diagnosis
 - Low platelet count (with normal WBC and RBC)
 - Otherwise normal blood smear
 - No apparent condition to blame it on
 - ***Note the lack of a definitive test***


Diagnosis of ITP

- Laboratory evidence of low platelet count
 - Check HCV and HIV antibodies in adults
- Blood smear examination to rule out other diagnoses
- Careful history (especially drug/toxin exposure) and physical exam
 - Should NOT have large liver, spleen, adenopathy
- Bone marrow examination is advised if exam findings are abnormal

Whom to Treat in ITP?

Key: Are They Bleeding or Not

- Normal platelet count 150,000-450,000/ μL
- Symptomatic patients with platelet counts $< 30,000-50,000/\mu\text{L}$
- Asymptomatic patients with counts below 10,000/ μL
- Treat with: Corticosteroid taper, IVIg





RhAPP


RHEUMATOLOGY ADVANCED
PRACTICE PROVIDERS

Hematologic Cancers: An Overview

Hematologic (Blood) Cancers: Causes and Risk Factors

- Proposed associations with environmental or external factors:
 - Agent Orange, benzene, radiation
- Leukemias and lymphomas are most common in caucasians; MM African American males
- Rare familial cases in MM, CLL are not well understood
- Smoking cigarettes (acute leukemia)

Remember This Slide?



Features of Common Blood Cancers

| | Acute Leukemias (AML and ALL) | MDS | Chronic Leukemias (CML and CLL) | Lymphomas (Hodgkins, Non- hodgkins) | Multiple Myeloma |
|------------------------------------|---|--|--|--|---|
| Definition | Increase of clonal immature "blasts" in the bone marrow which can be found in the blood | Spectrum of clonal, hematologic stem cell malignancies | Accumulation of lymphocyte clones in blood, bone marrow, and lymphoid tissue | Cancer of lymph nodes | Cancer of plasma cells |
| Epidemiology/Age | 14,590/Y, 67y (AML) 6,070/Y, 14y (ALL); 40% will be >20yrs | 15,000/Y (70y) | 5,920/Y, 64y(CML) 15,680/Y, 71y (CLL) | 9,290/Y, 38y (HL) 69,740 /Y, 66y (NHL) | 22,300/Y, 69y |
| Presentation/ Hallmarks | Anemia, infection, bleeding;F, WL | Anemia, infection, bleeding | Incidental, fevers, lymph node swelling; wl ns | fevers, lymph node swelling;; f,wl , ns | Kidney disease, protein in urine, bone pain, anemia; WL |
| Incidence | Age related Male>Female | Age related Female>Male | Age related Male>Female | Age related Male>Female | Age related Male>Female |


Overview of Hematologic Cancers. December 4, 2020 | 47.

F = fever; NS = night sweats; WL = weight loss.


Howlader N, Noone AM, Krapcho M, Garshell J, Neyman N, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). *SEER Cancer Statistics Review. 1975-2010*, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2010/, based on November 2012 SEER data submission, posted to the SEER web site, 2020.

Pathways of Lymphoma


- Lymphatic vessels, nodes, and organs
- Primary organs
 - BM, thymus
- Secondary organs
 - LNs
 - Spleen
 - MALT
 - Waldeyer's ring



Normal LN Organization



Flow Cytometry: The Zip Code for Primary Cell Type of B-Cell Neoplasms



Overview of Hematologic Cancers. December 4, 2020 | 50.
CML-LBC = chronic myeloid leukemia-lymphoid blast crisis; HL = Hodgkin lymphoma.
LeBien, et al. 2008.

Types of Leukemia, Lymphoma: Indolent to Aggressive

| Indolent | Aggressive | Very Aggressive |
|---|---|---|
| <p>CLL/SLL</p> <p>Lymphoplasmacytic/ Waldenstroms (WM)</p> <p>MZL</p> <p>Follicle center lymphoma, follicular, grade 1/2</p> <p>Most are incurable</p> <p>Goal is control and minimize symptoms</p> | <p>MCL</p> <p>Follicle center lymphoma, follicular, grade 3</p> <p>DLBCL</p> <p>Primary mediastinal large B-cell lymphoma</p> <p>Require immediate therapy</p> <p>Variable treatment goals</p> <p>Cure rates vary</p> | <p>Precursor B-lymphoblastic lymphoma/leukemia</p> <p>B-cell acute leukemia</p> <p>Therapy undertaken with curative intent</p> <p>Cure rates vary</p> |

Diagnostic Evaluation of Blood Cancers

| Diagnostic Study | Clinical Significance |
|---|--|
| CBC + differential + platelets Reticulocyte count | <ul style="list-style-type: none">Evaluate presence of cytopenias, lymphocytosis, morphological abnormalities, and BM response to anemia |
| LDH, haptoglobin, coombs, and reticulocyte count | <ul style="list-style-type: none">Evaluate for underlying hemolysis |
| LDH | <ul style="list-style-type: none">Necessary for risk stratification using IPIEvaluate for aggressive disease, risk for TLS, and hemolysis |
| Serum β_2m | <ul style="list-style-type: none">Prognostic relevanceReflects WBC membrane turnoverLevels are affected by renal function |
| Hepatic profile | <ul style="list-style-type: none">Treatments have potential renal and hepatic toxicities or may be affected by renal or hepatic insufficienciesSerum albumin reflects nutritional status and used to estimate prognosis |

Diagnostic Evaluation of Blood Cancers

| Diagnostic Study | Clinical Significance |
|-------------------------------|--|
| MUGA scan or echocardiogram | <ul style="list-style-type: none">• Baseline evaluation for patients receiving anthracycline therapy |
| CT chest, abdomen, and pelvis | <ul style="list-style-type: none">• Current standard of care for initial staging on NHL• Estimation of anatomic extent of disease and areas of abnormal LNs (> 1 cm) |
| ¹⁸ FDG-PET | <ul style="list-style-type: none">• PET with FDG shows functional metabolic status reported as SUV• Useful in evaluation of LNs < 1 cm• Scanning after a few cycles of therapy have been shown to predict treatment outcomes in MCL |
| CXR | <ul style="list-style-type: none">• Baseline evaluation for any underlying disease |

MUGA = multi-gated acquisition scan; CT = computed tomography;


¹⁸FDG-PET = 18-fluorodeoxyglucose-positron emission tomography; CXR = chest X-ray; LNs = lymph nodes;

SUV = standardized uptake value.

NCCN, 2020.

Diagnostic Evaluation of Blood Cancers

| Diagnostic Study | Clinical Significance |
|--|--|
| Aspirate | Evaluation of morphological abnormalities -flow cytometry, FISH analysis, and cytogenetics |
| Biopsy Should be of adequate size for evaluation (1–2 cm) | Cellularity, presence of lymphocytic infiltrates, exclusion of other BM disorders |
| Cytogenetics, FISH | “Blueprint” for prognosis; XY or XX |



Staging and Prognosis: Common Blood Cancers

| | Acute Leukemias (AML and ALL) | MDS | Chronic Leukemias (CML and CLL) | Lymphomas (Follicular, Diffuse large B-cell & Hodgkins) | Multiple Myeloma |
|----------------|--|---|---|---|--|
| Staging System | French-American-British (FAB) or WHO classification, FAB: subtypes, M0 through M7, based on blood counts, differentiation of cells; WHO: classifies according to genetic abnormalities | FAB, WHO; IPSS-r prognosis Looks at blasts, cytopenias, cytogenetics | CLL-Rai includes 5 stages of CLL: Stage 0, lymphocytosis only, best survival Stages III and IV are high risk with short survival (months), lymphocytosis, anemia, low plts CML "phases: CP, AP, and BP (mos) | Generally stage 1-IV; A= absence of b symptoms (night sweats, fevers, wt loss); B= presence Various prognosis systems NHL: International Prognostic Index (IPI) uses APLES for prognosis (age, PS, nodal sites) | International staging system (ISS) looks at two blood tests: Serum b2m, albumin |
| Prognosis | 90% of adults will die of acute leukemia | Higher blast count=higher risk of progression to AML | Lower stages =longer survival; years vs months | Lower stages =longer survival; years vs months | Median survival as high as 7.3 years with nl cytogenetics |
| Curable | In some with transplant | Generally not | Generally not with CLL; possibly with CML and new agents | In some with NHL, HD | Generally not |

Key Takeaways

- Abnormalities in ones' blood counts are a sign of an underlying condition, which may not often be serious
- Watchful waiting is often appropriate
- Consult hematology, Primary provider if unknown cause

Key Takeaways #2

- Blood cancers arise from the bone marrow
- Although most are incurable, most are highly treatable
- Knowledge of the basics of hematology will allow for prompt and appropriate evaluation and can make a difference!



Cleveland Clinic

Thank you!

